Dosing-Related Economics Arise During FDA Panel’s Arcapta Review
Executive Summary
The Pulmonary-Allergy Drugs Advisory Committee’s discussion of Novartis’ Arcapta Neohaler on March 8 briefly veered off in a direction that surely no sponsor wants to see, with panelists debating whether a drug should be dosed less frequently for economic reasons than proposed by the sponsor.
You may also be interested in...
COPD Drug Dose Selection May Face Greater Scrutiny In Arcapta’s Wake
FDA’s lingering concerns about the appropriate dose for Novartis’ chronic obstructive pulmonary disease therapy Arcapta Neohaler (indacaterol) suggest the agency will take a harder line on dosing data requirements for new COPD treatments, particularly when they have not first been approved in asthma.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.